Vancomycin dry powder inhalation - Savara Pharmaceuticals

Drug Profile

Vancomycin dry powder inhalation - Savara Pharmaceuticals

Alternative Names: AeroVanc; Vancomycin hydrochloride inhalation powder

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Savara Pharmaceuticals
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity No
  • Available For Licensing Yes - Methicillin-resistant Staphylococcus aureus infections

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • Phase I Bronchiectasis
  • Preclinical Nosocomial pneumonia

Most Recent Events

  • 08 May 2017 Savara Pharmaceuticals has patent protection for vancomycin dry powder inhalation in USA
  • 08 May 2017 Savara Pharmaceuticals receives patent allowance for vancomycin dry powder inhalation in Canada
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in Australia (Inhalation, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top